{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:14:52Z","timestamp":1780316092958,"version":"3.54.1"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    The Global Initiative for Asthma (GINA) report and national and international guidelines have shifted away from short-acting beta\n                    <jats:sub>2<\/jats:sub>\n                    -agonist (SABA)-only bronchodilators as first-line asthma rescue therapy, recognizing that both bronchoconstriction and inflammation underlie the increase in symptoms preceding an exacerbation. Instead, the GINA Committee supports strategies to reduce inflammation, such as anti-inflammatory reliever (AIR) therapy (as-needed, low-dose inhaled corticosteroid [ICS]\u2013formoterol or SABA\u2013ICS for symptom relief) and single maintenance and reliever therapy (SMART) or maintenance and reliever therapy (MART; i.e., ICS\u2013formoterol used as both maintenance and as-needed rescue therapy). This narrative review discusses the rationale behind the move toward AIR and SMART regimens, examining the inflammatory pathophysiology of exacerbations and how the ramp-up phase may represent a \u201cwindow of opportunity\u201d for prompt anti-inflammatory treatment to prevent exacerbations. Key clinical data from studies of AIR and SMART regimens, as well as the importance of as-needed SABA\u2013ICS use in routine clinical practice, are also discussed. The review highlights the importance of ICS delivery during times of wheezing and\/or symptoms to reduce the ongoing inflammatory cascade, thereby reducing the likelihood of initial symptoms developing into an exacerbation. In this way, patients can avoid the need for systemic corticosteroids, reducing the overall lifetime steroid load and the risk of lifetime dose-dependent complications such as bone thinning, diabetes, hypertension, and many other conditions.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1826737","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:59:55Z","timestamp":1780315195000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beta2-agonist and anti-inflammatory combination therapy for asthma rescue: a paradigm shift in asthma care"],"prefix":"10.3389","volume":"13","author":[{"given":"Neil","family":"Skolnik","sequence":"first","affiliation":[{"name":"Sidney Kimmel Medical College","place":["Jenkintown, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Stieritz","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College","place":["Jenkintown, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Akers","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Pharmaceutical Sciences, Washington State University","place":["Spokane, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Hudd","sequence":"additional","affiliation":[{"name":"Massachusetts College of Pharmacy and Health Sciences","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy L.","family":"Wright","sequence":"additional","affiliation":[{"name":"Wright & Associates Family Healthcare","place":["Amherst, NH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileen","family":"Gilbert","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals, United States Medical, AstraZeneca","place":["Wilmington, DE, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazrin","family":"Yusufova","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals, United States Medical, AstraZeneca","place":["Wilmington, DE, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Cook","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals, Global Medical Affairs, AstraZeneca","place":["Gaithersburg, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Robb","sequence":"additional","affiliation":[{"name":"Ernest Mario School of Pharmacy, Rutgers University","place":["Newark, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Naddaf","sequence":"additional","affiliation":[{"name":"The Toledo Clinic, Family Medicine","place":["Toledo, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"ref1","year":"2024"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"E53","DOI":"10.5888\/pcd21.240005","article-title":"The status of asthma in the United States","volume":"21","author":"Pate","year":"2024","journal-title":"Prev Chronic Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.12788\/jfp.0625","article-title":"Use of ICS and fast-acting bronchodilators in asthma: past, present, and future","volume":"72","author":"Skolnik","year":"2023","journal-title":"J Fam Pract"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41533-024-00399-2","article-title":"Best practice advice for asthma exacerbation prevention and management in primary care: an international expert consensus","volume":"34","author":"Skolnik","year":"2024","journal-title":"NPJ Prim Care Respir Med"},{"key":"ref5","first-page":"497","article-title":"An overview of health disparities in asthma","volume":"94","author":"Perez","year":"2021","journal-title":"Yale J Biol Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1038\/s41598-024-58429-5","article-title":"Asthma prevalence among United States population insights from NHANES data analysis","volume":"14","author":"Swed","year":"2024","journal-title":"Sci Rep"},{"key":"ref7","year":"2026"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/01.JAA.0000873824.54710.20","article-title":"Albuterol: still first-line in rescue therapy?","volume":"35","author":"Pitonzo","year":"2022","journal-title":"JAAPA"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1701103","DOI":"10.1183\/13993003.01103-2017","article-title":"The paradoxes of asthma management: time for a new approach?","volume":"50","author":"O'Byrne","year":"2017","journal-title":"Eur Respir J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jaip.2024.01.043","article-title":"The use of albuterol\/budesonide as reliever therapy to reduce asthma exacerbations","volume":"12","author":"Panettieri","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref11","year":"2019"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2147\/ppa.S209532","article-title":"New insights to improve treatment adherence in asthma and COPD","volume":"13","author":"George","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.jaip.2021.10.011","article-title":"A practical guide to implementing SMART in asthma management","volume":"10","author":"Reddel","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3399\/bjgp24X736353","article-title":"A simple and effective evidence-based approach to asthma management: ICS-formoterol reliever therapy","volume":"74","author":"Levy","year":"2024","journal-title":"Br J Gen Pract"},{"key":"ref15","volume-title":"Airsupra (Albuterol and Budesonide) Inhalation Aerosol, for Oral Inhalation Use: US Prescribing Information","year":"2025"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa2203163","article-title":"Albuterol-budesonide fixed-dose combination rescue inhaler for asthma","volume":"386","author":"Papi","year":"2022","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa2504544","article-title":"As-needed albuterol-budesonide in mild asthma","volume":"393","author":"LaForce","year":"2025","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group","volume":"146","author":"Cloutier","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"ref19","year":"2006"},{"key":"ref20","year":"2014"},{"key":"ref21","year":"2024"},{"key":"ref22","year":"2025"},{"key":"ref23","volume-title":"Spiriva","year":"2014"},{"key":"ref24","volume-title":"Advair Diskus (Fluticasone Propionate and Salmeterol Inhalation Powder), for Oral Inhalation Use: US Prescribing Information","year":"2019"},{"key":"ref25","volume-title":"Nucala (Mepolizumab) Injection, for Subcutaneous Use: US Prescribing Information","year":"2023"},{"key":"ref26","volume-title":"Trelegy Ellipta (Fluticasone Furoate, Umeclidinium, and Vilanterol Inhalation Powder), for Oral Inhalation Use: US Prescribing Information","year":"2023"},{"key":"ref27","volume-title":"Tezspire","year":"2023"},{"key":"ref28","volume-title":"Xolair","year":"2024"},{"key":"ref29","volume-title":"Fasenra (Benralizumab) Injection, for Subcutaneous Use: US Prescribing Information","year":"2024"},{"key":"ref30","volume-title":"Dupixent","year":"2024"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3389\/fped.2019.00246","article-title":"Epidemiology of asthma in children and adults","volume":"7","author":"Dharmage","year":"2019","journal-title":"Front Pediatr"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jacig.2022.06.001","article-title":"Age-dependent rebound in asthma exacerbations after COVID-19 lockdown","volume":"1","author":"Hazan","year":"2022","journal-title":"J Allergy Clin Immunol Glob"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.2147\/jaa.S326213","article-title":"Impact of socioeconomic status on adult patients with asthma: a population-based cohort study from UK primary care","volume":"14","author":"Busby","year":"2021","journal-title":"J Asthma Allergy"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"101367","DOI":"10.1016\/j.lanepe.2025.101367","article-title":"Association between income, employment status, and asthma outcomes: a systematic review and meta-analysis","volume":"56","author":"Gassasse","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.jaci.2021.10.007","article-title":"Socioeconomic disparities in asthma health care utilization, exacerbations, and mortality: a systematic review and meta-analysis","volume":"149","author":"Redmond","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"106949","DOI":"10.1016\/j.rmed.2022.106949","article-title":"The impact of inhaler technique on clinical outcomes in adolescents and adults with asthma: a systematic review","volume":"202","author":"Roche","year":"2022","journal-title":"Respir Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.anai.2010.10.006","article-title":"Relationship of asthma management, socioeconomic status, and medication insurance characteristics to exacerbation frequency in children with asthma","volume":"106","author":"Ungar","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records","volume":"33","author":"Kim","year":"2018","journal-title":"J Korean Med Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.4187\/respcare.03200","article-title":"Asthma and adherence to inhaled corticosteroids: current status and future perspectives","volume":"60","author":"B\u00e5rnes","year":"2015","journal-title":"Respir Care"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e080353","DOI":"10.1136\/bmj-2024-080353","article-title":"Optimising inhaled therapy for patients with asthma","volume":"386","author":"Bansal","year":"2024","journal-title":"BMJ"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12931-024-02937-5","article-title":"Small airway dysfunction links asthma exacerbations with asthma control and health-related quality of life","volume":"25","author":"Gao","year":"2024","journal-title":"Respir Res"},{"key":"ref42","year":"2025"},{"key":"ref43","year":"2023"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1164\/rccm.201901-0016OC","article-title":"The projected economic and health burden of uncontrolled asthma in the United States","volume":"200","author":"Yaghoubi","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"00726","DOI":"10.1016\/j.waojou.2022.100726","article-title":"Systemic corticosteroids in asthma: a call to action from World Allergy Organization and Respiratory Effectiveness Group","volume":"15","author":"Bleecker","year":"2022","journal-title":"World Allergy Organ J"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/jaa.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1800703","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur Respir J"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1164\/rccm.201808-1516OC","article-title":"Exacerbation patterns in adults with asthma in England. A population-based study","volume":"199","author":"Bloom","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.anai.2025.02.009","article-title":"Exacerbation burden in patients treated as intermittent or mild-persistent asthma using short-acting \u03b2","volume":"134","author":"Lugogo","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1164\/ajrccm.160.2.9811100","article-title":"Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group","volume":"160","author":"Tattersfield","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/jama.2024.22700","article-title":"Inhaled reliever therapies for asthma: a systematic review and meta-analysis","volume":"333","author":"Rayner","year":"2025","journal-title":"JAMA"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.molmed.2022.09.001","article-title":"Asthma exacerbations: the Achilles heel of asthma care","volume":"28","author":"McIntyre","year":"2022","journal-title":"Trends Mol Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3390\/cells11071105","article-title":"The role of airway epithelial cell alarmins in asthma","volume":"11","author":"Whetstone","year":"2022","journal-title":"Cells"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1056\/NEJMra1608969","article-title":"Severe and difficult-to-treat asthma in adults","volume":"377","author":"Israel","year":"2017","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"17534666211042534","DOI":"10.1177\/17534666211042534","article-title":"Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies","volume":"15","author":"Canonica","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1152\/japplphysiol.00950.2012","article-title":"Airway smooth muscle in the pathophysiology and treatment of asthma","volume":"114","author":"Doeing","year":"2013","journal-title":"J Appl Physiol (1985)"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jaip.2017.05.001","article-title":"Asthma exacerbations: pathogenesis, prevention, and treatment","volume":"5","author":"Castillo","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.anai.2021.01.024","article-title":"Real-world patterns and implications of short-acting \u03b2","volume":"126","author":"Lugogo","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"2101402","DOI":"10.1183\/13993003.01402-2021","article-title":"Short-acting \u03b2","volume":"59","author":"Bateman","year":"2022","journal-title":"Eur Respir J"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12890-024-03038-1","article-title":"SABINA\u202f+\u202fHong Kong: a territory wide study of prescribing trends and outcomes associated with the use of short-acting \u03b22 agonists in the Chinese population","volume":"24","author":"Fung","year":"2024","journal-title":"BMC Pulm Med"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3390\/jcm9040921","article-title":"Effective asthma management: is it time to let the AIR out of SABA?","volume":"9","author":"Kaplan","year":"2020","journal-title":"J Clin Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1378\/chest.129.1.15","article-title":"The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol","volume":"129","author":"Nelson","year":"2006","journal-title":"Chest"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"00140","DOI":"10.1183\/23120541.00140-2022","article-title":"SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada)","volume":"8","author":"Noorduyn","year":"2022","journal-title":"ERJ Open Res"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1901872","DOI":"10.1183\/13993003.01872-2019","article-title":"Overuse of short-acting \u03b2","volume":"55","author":"Nwaru","year":"2020","journal-title":"Eur Respir J"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/j.jaip.2022.02.047","article-title":"Short-acting beta-2-agonist exposure and severe asthma exacerbations: SABINA findings from Europe and North America","volume":"10","author":"Quint","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.anai.2023.06.018","article-title":"Patterns of rescue and maintenance therapy claims surrounding a clinical encounter for an asthma exacerbation","volume":"131","author":"Lanz","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4103\/1817-1737.65040","article-title":"Genomic and non-genomic actions of glucocorticoids in asthma","volume":"5","author":"Alangari","year":"2010","journal-title":"Ann Thorac Med"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1378\/chest.09-0354","article-title":"Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting beta-agonists","volume":"136","author":"Black","year":"2009","journal-title":"Chest"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"15285","DOI":"10.3390\/ijms232315285","article-title":"The impact of corticosteroids on human airway smooth muscle contractility and airway hyperresponsiveness: a systematic review","volume":"23","author":"Calzetta","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"L345","DOI":"10.1152\/ajplung.00393.2019","article-title":"Budesonide enhances agonist-induced bronchodilation in human small airways by increasing cAMP production in airway smooth muscle","volume":"318","author":"Koziol-White","year":"2020","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tips.2018.11.002","article-title":"Non-genomic effects of glucocorticoids: an updated view","volume":"40","author":"Panettieri","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/j.1398-9995.2008.01725.x","article-title":"Glucocorticoids inhibit degranulation of mast cells in allergic asthma via nongenomic mechanism","volume":"63","author":"Zhou","year":"2008","journal-title":"Allergy"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jaip.2023.01.010","article-title":"\"As-needed\" inhaled corticosteroids for patients with asthma","volume":"11","author":"Cardet","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1164\/rccm.200407-884OC","article-title":"Budesonide\/formoterol combination therapy as both maintenance and reliever medication in asthma","volume":"171","author":"O'Byrne","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/s2213-2600(13)70012-2","article-title":"Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial","volume":"1","author":"Papi","year":"2013","journal-title":"Lancet Respir Med"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/s0140-6736(06)69284-2","article-title":"Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study","volume":"368","author":"Rabe","year":"2006","journal-title":"Lancet"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"e220615","DOI":"10.1001\/jamanetworkopen.2022.0615","article-title":"Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma: a systematic review and meta-analysis","volume":"5","author":"Beasley","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/s2213-2600(13)70007-9","article-title":"Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial","volume":"1","author":"Patel","year":"2013","journal-title":"Lancet Respir Med"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/j.jaip.2023.03.046","article-title":"Safety and effectiveness of as-needed formoterol in asthma patients taking inhaled corticosteroid (ICS)-formoterol or ICS-salmeterol maintenance therapy","volume":"11","author":"Reddel","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1715275","article-title":"As-needed budesonide-formoterol versus maintenance budesonide in mild asthma","volume":"378","author":"Bateman","year":"2018","journal-title":"N Engl J Med"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1056\/NEJMoa1715274","article-title":"Inhaled combined budesonide-formoterol as needed in mild asthma","volume":"378","author":"O'Byrne","year":"2018","journal-title":"N Engl J Med"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1901963","article-title":"Controlled trial of budesonide\u2013formoterol as needed for mild asthma","volume":"380","author":"Beasley","year":"2019","journal-title":"N Engl J Med"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(19)31948-8","article-title":"Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial","volume":"394","author":"Hardy","year":"2019","journal-title":"Lancet"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jaip.2019.06.030","article-title":"A pragmatic trial of symptom-based inhaled corticosteroid use in African-American children with mild asthma","volume":"8","author":"Sumino","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S0140-6736(25)00861-X","article-title":"Budesonide\u2013formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial","volume":"406","author":"Hatter","year":"2025","journal-title":"Lancet"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.chest.2023.03.035","article-title":"Albuterol-budesonide pressurized metered dose inhaler in patients with mild-to-moderate asthma: results of the DENALI double-blind randomized controlled trial","volume":"164","author":"Chipps","year":"2023","journal-title":"Chest"},{"key":"ref89","year":"2025"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/ACI.0000000000000870","article-title":"Consequences of severe asthma exacerbations","volume":"23","author":"Busse","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.anai.2025.07.008","article-title":"Albuterol\u2013budesonide rescue inhaler for asthma: patterns of use and safety in the MANDALA trial","volume":"136","author":"Chipps","year":"2026","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1183\/09031936.00075614","article-title":"Medication adherence and the risk of severe asthma exacerbations: a systematic review","volume":"45","author":"Engelkes","year":"2015","journal-title":"Eur Respir J"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jaci.2007.08.020","article-title":"Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence","volume":"120","author":"Williams","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2466-6-13","article-title":"Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study","volume":"6","author":"Partridge","year":"2006","journal-title":"BMC Pulm Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1826737\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:59:58Z","timestamp":1780315198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1826737\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":94,"alternative-id":["10.3389\/fmed.2026.1826737"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1826737","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"1826737"}}